Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (PSMA) (FOLH1) and CD3 (CD3E) · developed by AMGEN
Acapatamab is a half-life extended bispecific T-cell engager composed of two single-chain variable fragments, one binding PSMA on prostate cancer cells and one binding CD3 on cytotoxic T lymphocytes. It redirects T cells to PSMA-expressing tumor cells, causing their destruction. It is being studied in metastatic castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03792841 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Terminated | AMGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Castration-resistant Prostate CancerProstate Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the AMGN page.
See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AMGN catalysts and pipeline →